Join our CME-accredited webinar with Unilabs Middle East! Hemmel Amrania PhD presents Digistain's clinical validation for its SAME DAY breast cancer recurrence risk test vs the standard 2-8 wk wait.  🔬 Ideal for Oncology Professionals. Register now! 👇 lnkd.in/dvph-iRq

Digistain continues to expand its international clinical development network, with meetings in China focused on promoting collaborative research. #Digistain #HealthTech #ClinicalTrials #Oncology #ChinaExpansion #breastcancercare #MedicalResearch #TumorIntelligence

We were honoured to attend South Summit Brazil 2026 as part of the EUREKA Investment Readiness Programme, which provided a valuable platform to engage with investors, partners, and the wider innovation ecosystem. Thank you to the EUREKA Network for supporting our participation.

Digistain was pleased to be represented at the Thailand Board of Investment roundtable hosted at the Thai Embassy in London. It's conversations like these play an important role in shaping partnerships, that can deliver our mission to improve patient outcomes across SEA.

We are delighted to announce that Digistain has secured the rights to distribute Rhythym Bioscience's geneType genetic test portfolio across Southeast Asia.  To read more about the partnership, you can access the full press release here: rhythmbio.com/investor-cente…

We’re delighted to share that we’ve been selected as one of just 27 companies by EUREKA to participate in a mission to South Summit Brazil, taking place from 25 to 27 March. If you’re attending South Summit Brazil, we would love to connect and we hope to see you there!

Merry Christmas and Happy New Year from Digistain  Here’s to a prosperous and impactful 2026.

We were thrilled to showcase Digistain at #BIGOSA2025 with Key Oncologics, where we had some excellent conversations and gained valuable insights. Here we reaffirm our commitment to support improved #cancercare in South Africa and look forward to future opportunities.

We are proud to announce that following the official launch of Digistain in South Africa last month, the technology has already been successfully integrated into routine clinical practice by local oncologists. #HealthcareInnovation #cancerresearch #breastcancerawareness

Dr. Hemmel Amrania, CEO of Digistain, will be delivering a keynote at the AI4Health.Cro Consortium Annual Conference today, April 8th, 2025, at the Hotel Zonar, Zagreb.  #AI4Health #CancerDiagnostics #MedTech #Oncology #AI #HealthcareInnovation #BreastCancer #Zagreb #Digistain

We’re excited to highlight some of the key features of the Digistain test that could make a real difference for you or your patients. To learn more about how Digistain could help, visit our website: digistain.co.uk #BreastCancerAwareness #RiskStratification #CancerCare

We're excited to share that Digistain is now being used by patients covered by one of the top four health insurers in the U.S. A big thank you to our incredible team, partners, and supporters who make this progress possible! #CancerDiagnostics #PrecisionMedicine

Delighted to have Dr. Mel Valerie Cruz-Ordinario present to doctors at St. Luke’s Medical Center Quezon City, Philippines, sharing her specialist insight on the benefits of Digistain for precision risk stratification in breast cancer patients.

This World Cancer Day 2025, we proudly reaffirm our commitment to transforming cancer care through innovation and compassion.

A massive honour to recently host Professor Samuel Haryono from the Siloam Group Indonesia during his visit to the Digistain research lab at Imperial College London. #CancerCare #PrecisionMedicine #Digistain #MedicalResearch #GlobalHealth #CancerDiagnostics

Did you know? Digistain was incubated at Imperial College London and still runs its R&D lab there! 🔬 Founded in 1907, Imperial is a global leader in science, engineering, medicine, and business, ranked #1 in the UK and Europe, and #2 in the world (QS World Rankings 2025). 🌍🎓

We’re proud to show the incredible work being done by Shawn Chong and team with dedicated doctors in Indonesia who are supporting us in our mission to help close the gap in healthcare inequalities globally by providing an accessible solution for breast cancer risk stratification.

Following our partnership with Deloitte, we had the privilege of speaking with Senior Manager Roberto Vittandi, who shared his insights on Digistain and it's potential.  We believe collaboration drives innovation, and we're excited to be on this journey together!

Watch Professor Charles Coombes & Dr. Hemmel Amrania discuss the future of #RiskStratification in #BreastCancer and how Digistain is making it quicker & more accessible for patients everywhere. #CancerCare #HealthTech #Oncology youtube.com/watch?v=WhxNyA8N…